

Charles C Wykoff

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1320078/charles-c-wykoff-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

8,976
citations

33
h-index

94
g-index

173
ext. papers

10,598
ext. citations

5
avg, IF

5.84
L-index

#	Paper	IF	Citations
147	Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.. <i>Lancet, The</i> , 2022 ,	4.0	19
146	Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in DME: Radiomics Insights from the IMAGINE Study. <i>Ophthalmology Science</i> , 2022 , 100123		
145	YOSEMITE and RHINE. <i>Ophthalmology Science</i> , 2022 , 2, 100111		1
144	Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.. <i>Eye</i> , 2022 ,	4.4	2
143	Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience.. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2022 , 53, 257-265	1.4	0
142	Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. <i>JAMA Ophthalmology</i> , 2021 ,	3.9	5
141	Weakly-Supervised Vessel Detection in Ultra-Widefield Fundus Photography via Iterative Multi-Modal Registration and Learning. <i>IEEE Transactions on Medical Imaging</i> , 2021 , 40, 2748-2758	11.7	8
140	Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. <i>Ophthalmology Retina</i> , 2021 , 5, 224-233	3.8	2
139	Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. <i>BioDrugs</i> , 2021 , 35, 303-323	7.9	0
138	Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2021 , 5, 409-419	3.8	3
137	RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021 , 41, 1579-1586	3.6	2
136	Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2021 , 139, 542-547	3.9	1
135	Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. <i>British Journal of Ophthalmology</i> , 2021 ,	5.5	1
134	Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 743-752	1.9	5
133	Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. <i>American Journal of Ophthalmology</i> , 2021 , 226, 126-136	4.9	4
132	Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. <i>Ophthalmology Retina</i> , 2021 ,	3.8	1
131	Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. <i>British Journal of Ophthalmology</i> , 2021 , 105, 253-257	5.5	1

130	Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. <i>Ophthalmology Retina</i> , 2021 , 5, 348-356	3.8	9
129	Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. <i>Ophthalmology Retina</i> , 2021 , 5, 60-70	3.8	10
128	Quantitative Comparison of Fundus Images by 2 Ultra-Widefield Fundus Cameras. <i>Ophthalmology Retina</i> , 2021 , 5, 450-457	3.8	4
127	Reply. <i>Ophthalmology Retina</i> , 2021 , 5, e1-e2	3.8	
126	Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. <i>American Journal of Ophthalmology</i> , 2021 , 222, 328-339	4.9	9
125	THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review. <i>Retina</i> , 2021 , 41, 1-19	3.6	14
124	Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. <i>Diabetes Care</i> , 2021 , 44, 748-756	14.6	15
123	Reply. <i>Retina</i> , 2021 , 41, e56-e58	3.6	
122	Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. <i>American Journal of Ophthalmology</i> , 2021 , 235, 131-142	4.9	0
121	Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2021 , 139, 946-955	3.9	11
120	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. <i>Ophthalmology</i> , 2021 , 128, 1325-1336	7.3	11
119	Cooling Anesthesia for Intravitreal Injection: Results of the Prospective Open-Label, Dose-Ranging COOL-1 Trial.. <i>Clinical Ophthalmology</i> , 2021 , 15, 4659-4666	2.5	0
118	Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders. <i>Translational Vision Science and Technology</i> , 2020 , 9, 27	3.3	5
117	Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. <i>Ophthalmology</i> , 2020 , 127, 1179-1188	7.3	11
116	New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium. <i>International Journal of Retina and Vitreous</i> , 2020 , 6, 18	2.9	10
115	Abicipar pegol for neovascular age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 999-1008	5.4	13
114	THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. <i>Retina</i> , 2020 , 40, 552-556	3.6	3
113	American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema. <i>Journal of Vitreoretinal Diseases</i> , 2020 , 4, 125-135	0.7	6

112	Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice. <i>American Journal of Ophthalmology</i> , 2020 , 215, 66-71	4.9	7
111	Effects of Long-Term DME Control With 0.2 µg/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2020 , 51, 658-667	1.4	1
110	Iodine Allergy and the Use of Povidone Iodine for Endophthalmitis Prophylaxis. <i>Journal of Vitreoretinal Diseases</i> , 2020 , 4, 65-68	0.7	2
109	Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. <i>Ophthalmology</i> , 2020 , 127, 769-783	7.3	22
108	Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor Inhibitor for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. <i>Ophthalmology</i> , 2020 , 127, 211-220	7.3	8
107	SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. <i>Retina</i> , 2020 , 40, 1029-1037	3.6	6
106	Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. <i>American Journal of Ophthalmology</i> , 2020 , 210, 86-96	4.9	7
105	Rationale for American Society of Retina Specialists Best Practice Recommendations for Conducting Vitreoretinal Surgery during the COVID-19 Era. <i>Journal of Vitreoretinal Diseases</i> , 2020 , 4, 420-429	0.7	1
104	A Novel Deep Learning Pipeline for Retinal Vessel Detection In Fluorescein Angiography. <i>IEEE Transactions on Image Processing</i> , 2020 ,	8.7	16
103	RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. <i>Retina</i> , 2020 , 40, 2175-2183	3.6	4
102	Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. <i>PLoS ONE</i> , 2020 , 15, e0238958	3.7	2
101	Ophthalmology conferences in the coronavirus disease 2019 era. <i>Current Opinion in Ophthalmology</i> , 2020 , 31, 396-402	5.1	10
100	Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. <i>American Journal of Ophthalmology</i> , 2020 , 209, 99-106	4.9	12
99	Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. <i>Eye</i> , 2020 , 34, 480-490	4.4	11
98	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. <i>Ophthalmology</i> , 2020 , 127, 186-195	7.3	101
97	Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. <i>Acta Ophthalmologica</i> , 2019 , 97, 460-472	3.7	30
96	Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. <i>American Journal of Ophthalmology</i> , 2019 , 206, 154-160	4.9	16
95	Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study. <i>Ophthalmology</i> , 2019 , 126, 1171-1180	7.3	19

94	Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. <i>Ophthalmology Retina</i> , 2019 , 3, 656-662	3.8	11
93	Evidence-Based Guidelines for Management of Diabetic Macular Edema. <i>Journal of Vitreoretinal Diseases</i> , 2019 , 3, 145-152	0.7	4
92	Simultaneous Inhibition of Angiotensin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. <i>Ophthalmology</i> , 2019 , 126, 1155-1170	7.3	95
91	Diabetic Retinopathy and Its Management 2019 , 39-51		
90	Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2019 , 206, 74-81	4.9	11
89	Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. <i>American Journal of Ophthalmology</i> , 2019 , 202, 91-99	4.9	27
88	Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes. <i>American Journal of Ophthalmology Case Reports</i> , 2019 , 15, 100492	1.3	
87	Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. <i>Ophthalmology Retina</i> , 2019 , 3, 1076-1086	3.8	19
86	Protecting Vision in Patients With Diabetes With Ultra-Widefield Imaging: A Review of Current Literature. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019 , 50, 639-648	1.4	4
85	Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019 , 50, e250-e256	1.4	1
84	Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (<i>Ophthalmology</i> . 2018;125:1047-1053). <i>Ophthalmology</i> , 2019 , 126, e18-e19	7.3	0
83	Age-Related Macular Degeneration: Clinical Management 2019 , 53-66		
82	Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection. <i>Journal of Vitreoretinal Diseases</i> , 2019 , 3, 411-419	0.7	3
81	Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. <i>Graefers Archive for Clinical and Experimental Ophthalmology</i> , 2019 , 257, 883-889	3.8	10
80	Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019 , 137, 65-73	3.9	60
79	Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform. <i>Diabetes Research and Clinical Practice</i> , 2018 , 140, 265-270	7.4	7
78	Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. <i>Graefers Archive for Clinical and Experimental Ophthalmology</i> , 2018 , 256, 511-518	3.8	16
77	Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. <i>Ophthalmology</i> , 2018 , 125, 683-690	7.3	31

76	Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. <i>Ophthalmology Retina</i> , 2018 , 2, 320-328	3.8	39
75	Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion 2018 , 59, 3278-3285		15
74	Five-Year Outcomes of Surgically Treated Symptomatic Epiretinal Membranes With and Without Internal Limiting Membrane Peeling. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, 296-302	1.4	9
73	Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial. <i>Ophthalmology Retina</i> , 2018 , 2, 874-877	3.8	28
72	Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. <i>Ophthalmology</i> , 2018 , 125, 1304-1306	7.3	1
71	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, S3-S15	1.9	59
70	Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2018 , 2, 997-1009	3.8	39
69	Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, 258-264	1.4	2
68	Predictors of Visual Acuity Outcomes Following Vitrectomy for Idiopathic Macular Hole. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, 566-570	1.4	2
67	Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, 692-697	1.4	13
66	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, 913-917	1.4	10
65	Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. <i>British Journal of Ophthalmology</i> , 2018 , 102, 631-636	5.5	21
64	Diagnostic and Therapeutic Challenges. <i>Retina</i> , 2018 , 38, 203-206	3.6	
63	Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. <i>British Journal of Ophthalmology</i> , 2018 , 102, 460-464	5.5	31
62	Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. <i>American Journal of Ophthalmology</i> , 2018 , 192, 84-90	4.9	3
61	Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. <i>Ophthalmology</i> , 2017 , 124, 440-449	7.3	39
60	Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes. <i>Ophthalmology</i> , 2017 , 124, 583-595	7.3	91
59	Diabetic Retinopathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017 , 40, 412-418	14.6	357

58	Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study. <i>Ophthalmology Retina</i> , 2017 , 1, 314-321	3.8	56
57	Impact of intravitreal pharmacotherapies including anti-vascular endothelial growth factor and corticosteroid agents on diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2017 , 28, 213-218	5.1	27
56	Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. <i>American Journal of Ophthalmology</i> , 2017 , 180, 8-17	4.9	41
55	THE ASSOCIATION OF EPIRETINAL MEMBRANE WITH MACULAR HOLE FORMATION AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. <i>Retina</i> , 2017 , 37, 1073-1078	3.6	24
54	Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. <i>American Journal of Ophthalmology</i> , 2017 , 180, 110-116	4.9	52
53	Reply. <i>American Journal of Ophthalmology</i> , 2017 , 177, 236-237	4.9	
52	Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. <i>Ophthalmology</i> , 2017 , 124, 919-921	7.3	18
51	Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. <i>JAMA Ophthalmology</i> , 2017 , 135, 107-114	3.9	5
50	Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID. <i>Ophthalmology Retina</i> , 2017 , 1, 382-388	3.8	12
49	Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. <i>Ophthalmology Retina</i> , 2017 , 1, 413-420	3.8	8
48	Intravitreal aflibercept for proliferative diabetic retinopathy. <i>Lancet, The</i> , 2017 , 390, 2141	4.0	2
47	Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. <i>Ophthalmology</i> , 2017 , 124, 74-81	7.3	50
46	Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. <i>Ophthalmology</i> , 2017 , 124, 215-223	7.3	40
45	Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. <i>American Journal of Ophthalmology</i> , 2017 , 173, 56-63	4.9	23
44	Subconjunctival Silicon Oil Cysts. <i>Ophthalmology Retina</i> , 2017 , 1, 560	3.8	
43	Positive Visual Phenomena Following Implantation of the Argus II Retinal Prosthesis. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017 , 48, 1022-1025	1.4	1
42	Diagnostic and Therapeutic Challenges. <i>Retina</i> , 2016 , 36, 2239-2245	3.6	
41	Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. <i>Ophthalmology</i> , 2016 , 123, 1716-1721	7.3	33

40	DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 308-12	1.4	8
39	ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. <i>Retina</i> , 2016 , 36, 1349-56	3.6	26
38	CHOROIDAL NEOVASCULARIZATION SECONDARY TO ALEXANDRITE LASER EXPOSURE. <i>Retinal Cases and Brief Reports</i> , 2016 , 10, 244-8	1.1	13
37	GRANULAR HYPERREFLECTIVE SPECKS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS SIGNS OF WEST NILE VIRUS INFECTION: THE STARDUST SIGN. <i>Retinal Cases and Brief Reports</i> , 2016 , 10, 349-53	1.1	1
36	Progressive retinal nonperfusion in ischemic central retinal vein occlusion. <i>Retina</i> , 2015 , 35, 43-7	3.6	28
35	Not All Retina Is Created Equal: Metabolic Quantification of Ultra-Widefield Images. <i>Ophthalmology</i> , 2015 , 122, 2580-2	7.3	5
34	Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2015 , 50, 373-7	1.4	17
33	Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. <i>Ophthalmology</i> , 2015 , 122, 2514-22	7.3	177
32	Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010). <i>American Journal of Ophthalmology</i> , 2015 , 159, 257-64.e1	4.9	33
31	Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015 , 46, 302-5	1.4	12
30	Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. <i>Ophthalmology</i> , 2014 , 121, 2432-42	7.3	54
29	Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). <i>British Journal of Ophthalmology</i> , 2014 , 98, 951-5	5.5	65
28	Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. <i>Retina</i> , 2014 , 34, 1728-35	3.6	66
27	Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. <i>Retina</i> , 2014 , 34, 48-54	3.6	17
26	Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. <i>Ophthalmology</i> , 2014 , 121, 1783-9	7.3	130
25	Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014 , 45, 312-7	1.4	61
24	Lasers for the treatment of intraocular tumors. <i>Lasers in Medical Science</i> , 2013 , 28, 1025-34	3.1	16
23	Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. <i>Ophthalmology</i> , 2013 , 120, 1945-6.e1	7.3	14

22	Laser treatment for retinopathy of prematurity. <i>Lasers in Medical Science</i> , 2013 , 28, 683-92	3.1	22
21	Purtscher-like retinopathy associated with pemphigus vulgaris. <i>Retinal Cases and Brief Reports</i> , 2013 , 7, 304-6	1.1	2
20	SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013 , 44, 121-6	1.4	19
19	Anti-vascular endothelial growth factor agents for pediatric retinal diseases. <i>International Ophthalmology Clinics</i> , 2011 , 51, 185-99	1.7	7
18	Fovea-sparing retinal detachments: time to surgery and visual outcomes. <i>American Journal of Ophthalmology</i> , 2010 , 150, 205-210.e2	4.9	35
17	Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital (2002-2009). <i>American Journal of Ophthalmology</i> , 2010 , 150, 392-398.e2	4.9	85
16	Intraoperative OCT of a full-thickness macular hole before and after internal limiting membrane peeling. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010 , 41, 7-11	1.4	38
15	Simultaneous presentation of retinoblastoma and morning glory disk anomaly. <i>Retinal Cases and Brief Reports</i> , 2009 , 3, 354-7	1.1	
14	Photodynamic therapy of bullous central serous chorioretinopathy with subretinal exudate and a tear of the retinal pigment epithelium. <i>Retinal Cases and Brief Reports</i> , 2009 , 3, 218-23	1.1	1
13	Diffuse neonatal hemangiomatosis presenting as bilateral iris hemangiomas in an infant. <i>Retinal Cases and Brief Reports</i> , 2009 , 3, 279-82	1.1	
12	Exogenous fungal endophthalmitis: microbiology and clinical outcomes. <i>Ophthalmology</i> , 2008 , 115, 1501-7, 1507.e1-2	7.3	129
11	Atypical teratoid/rhabdoid tumor arising from the third cranial nerve. <i>Journal of Neuro-Ophthalmology</i> , 2008 , 28, 207-11	2.6	10
10	Myopic laser in situ keratomileusis in eyes with thick corneas. <i>Journal of Cataract and Refractive Surgery</i> , 2006 , 32, 900-1	2.3	0
9	Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. <i>Journal of Biological Chemistry</i> , 2004 , 279, 42719-25	5.4	127
8	Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 473-82	2.2	229
7	HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. <i>Cancer Cell</i> , 2002 , 1, 459-68	24.3	410
6	Analysis of gene expression in ductal carcinoma in situ of the breast. <i>Clinical Cancer Research</i> , 2002 , 8, 3788-95	12.9	57
5	Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3660-8	2.2	367

4	Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. <i>American Journal of Pathology</i> , 2001 , 158, 1011-9	5.8	194
3	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. <i>Oncogene</i> , 2000 , 19, 6297-305	9.2	229
2	The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. <i>Nature</i> , 1999 , 399, 271-5	50.4	3980
1	Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. <i>Journal of Biological Chemistry</i> , 1997 , 272, 16374-81	5.4	307